Quantcast

Latest Angiogenesis Stories

2014-09-18 08:26:01

-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA(TM)) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma were published in the online version of The Lancet Oncology. In the trial, known as RAINBOW, the addition of ramucirumab to...

2014-09-12 08:25:08

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA(TM)) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. The global, randomized, double-blind study compared ramucirumab...

2014-09-08 23:05:50

Okyanos Heart Institute Now Accepting Qualified Heart Disease Candidates for Adult Stem Cell Treatment in New State-of-the-Art Cath Lab Freeport, Grand Bahama (PRWEB) September 08, 2014 Adult stem cell therapy for heart disease has emerged as a new treatment alternative for those living with a poor quality of life as a result of severe coronary artery disease. Okyanos is slated to begin delivering this innovative new treatment in the next several weeks, and is now screening qualified...

2014-08-14 08:28:34

ROCKVILLE, Md., Aug. 14, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three and six months ended June 30, 2014. http://photos.prnewswire.com/prnvar/20140706/124566 CASI reported a net loss for the second quarter of 2014 of ($1.6 million), or ($0.06) per share. This compares with a net loss of ($1.9 million), or...

2014-08-13 08:26:49

SAN DIEGO, Aug. 13, 2014 /PRNewswire/ -- Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is "highly warranted" to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional...

2014-07-21 20:22:14

CORALVILLE, Iowa, July 21, 2014 /PRNewswire/ -- McCord Research, Inc. was recently granted a second US patent (U.S. Patent No. 8,796,315). This patent describes a method for accelerating wound closure to improve wound healing. According to the inventor, Dr. McCord, this method includes administering or transplanting to individuals who require wound healing, a composition of an effective amount of hydroxytyrosol and oleuropein and cells derived from umbilical cord blood, such that the...

2014-07-10 23:07:39

A form of Vitamin E has been found to block a protein that mesothelioma cells need to form new blood vessels. Raleigh, NC (PRWEB) July 10, 2014 Scientists in Japan say mesothelioma cells respond to an altered form of α-tocotrienol (Vitamin E) by producing less of a protein that helps grow new blood vessels. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now. Researchers at Toyo University’s Graduate School of Life Sciences exposed...

2014-07-07 08:27:35

ROCKVILLE, Md., July 7, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). http://photos.prnewswire.com/prnvar/20140706/124566...

2014-06-25 12:29:13

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19(th), is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at...

2014-06-25 08:31:22

LONDON, June 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Triple Analysis: Melanoma, Angiogenesis and Cancer Vaccineshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/triple_analysis_melanoma_angiogenesis_cancer_vaccines.html This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.